Navigation Links
Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes
Date:9/3/2013

t of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit http://www.oramed.com

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, revolutionizing the treatment of diabetes with our products, and ORMD-0901 being a more patient-friendly form of treatment or it addressing a significant market. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader
2. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
3. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
4. Oramed Pharmaceuticals Announces Reverse Stock Split
5. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
6. Marrone Bio Innovations Submits New Bioherbicide for EPA Registration
7. Janssen Submits Additional Marketing Applications for ZYTIGA® in the U.S. and European Union
8. iBio, Inc. Submits Plan to Satisfy NYSE Amex Continued Listing Standards
9. WellnessFX Launches New Products e-HealthAnswers and Womens Fertility Package
10. XY Precision Positioning Stage Provides Nanometer Incremental Motion in a Small Package: PI introduces Affordable 2-Axis Piezo Positioner, Model P-763
11. FDA/PhUSE Collaboration: Study Data Reviewer’s Guide Work Package v1.1 Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Florida (PRWEB) , ... September 02, 2015 , ... ... been treated and managed with the use of special anti-vascular endothelial growth factor ... in many more patients, currently does not have a scientific protocol for the ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Biomarkers ... offering. This report follows the broad ... can be objectively measured and evaluated as an ... well as pharmacological responses to a therapeutic intervention. ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ... report "Gene Therapy - Technologies, Markets and Companies" ... gene therapy are difficult to estimate as there is ... marketed in China since 2004. ... The estimates are based on epidemiology of diseases to ...
(Date:9/2/2015)... 2015 Research ... the addition of Jain PharmaBiotech,s new report ... to their offering. The ... fluorescence in situ hybridization (FISH), comparative genomic ... includes application of nanobiotechnology, microarrays, real-time polymerase ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3
... Genaera,Corporation (Nasdaq: GENR ) today announced its financial ... net loss for the year ended,December 31, 2007 was $15.7 ... a net loss of $21.2 million, or $(1.46) per share,basic ... net loss for,the quarter ended December 31, 2007 was $5.8 ...
... to Move ... Science Forward, MUNICH, Germany, March 31 ... serving science, today,launched a number of innovative new products at Analytica 2008, ... - 4. The company,s new technologies are focused on enabling,customers to take ...
... ImaRx Therapeutics, Inc., a,biopharmaceutical company developing and commercializing ... with fourth,quarter and full year 2007 financial results., ... TUCSON Phase I/II clinical study -- Received ... Kinlytic(TM) -- ...
Cached Biology Technology:Genaera Corporation Announces 2007 Financial Results 2Genaera Corporation Announces 2007 Financial Results 3Genaera Corporation Announces 2007 Financial Results 4Genaera Corporation Announces 2007 Financial Results 5Genaera Corporation Announces 2007 Financial Results 6Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 2Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 3Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 4Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 5Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 6Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 7ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 2ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 3ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 4ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 5ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 6ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 7ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 8ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 9ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 10
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
(Date:8/12/2015)... 2015  New research unveiled at Black Hat ... to steal users, fingerprints. Information released today by ... scanners on mobile devices, making the security of ... on mobile devices, HYPR Corp. recently released a ... systems with strong cryptographic security. More information on ...
(Date:8/6/2015)... 6, 2015  Today, U.S. Congressman Mike ... ™ to learn firsthand how Silicon Valley technologies ... is a world leader in multi-factor identity management ... helping federal agencies and commercial organizations achieve new ... "The vast majority of network breaches can ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Rep. Honda to Visit Crossmatch in Redwood City 2
... observed behavior and characteristics is well-established, a comprehensive ... lacking. There are also many lingering mysteries surrounding the ... why sex is such a prevalent reproductive strategy. A ... Jilin University in Jilin, China; and the State University ...
... car; it is difficult to make out anything in the pitch ... the road, but the driver cannot respond in time. When it ... the human eye and defusing such dangerous situations. They detect infrared ... creature and in case of danger, warn the driver through ...
... are delicate green insects with large, lace-like wings that ... Adults mostly feed on flowers, but the larvae are ferocious ... their prey on their backs after killing them using their ... new species of green lacewing in the genus Semachrysa ...
Cached Biology News:Physics and math shed new light on biology by mapping the landscape of evolution 2Cost-effective production of infrared lenses 2
... sets a new standard for high performance ... new design in instrumentation, this easy-to-use benchtop ... The BD FACSAria instrument is the first ... flow cell. This new flow cell ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
Biology Products: